You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 24, 2024

CLINICAL TRIALS PROFILE FOR AZACITIDINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Azacitidine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004062 ↗ Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer Completed National Cancer Institute (NCI) Phase 1 1999-07-01 RATIONALE: Azacitidine may help thyroid cancer cells regain the ability to take up iodine. This would allow the cancer to be detected and treated by radioactive iodine. PURPOSE: Phase I trial to study the effectiveness of azacitidine to restore thyroid function in treating patients who have persistent or metastatic thyroid cancer.
NCT00004062 ↗ Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer Completed Lucille P. Markey Cancer Center at University of Kentucky Phase 1 1999-07-01 RATIONALE: Azacitidine may help thyroid cancer cells regain the ability to take up iodine. This would allow the cancer to be detected and treated by radioactive iodine. PURPOSE: Phase I trial to study the effectiveness of azacitidine to restore thyroid function in treating patients who have persistent or metastatic thyroid cancer.
NCT00004871 ↗ Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed National Cancer Institute (NCI) Phase 1 2000-05-01 RATIONALE: Azacitidine plus phenylbutyrate may help leukemia cells develop into normal white blood cells. PURPOSE: Phase I trial to study the effectiveness of combining azacitidine and phenylbutyrate in treating patients who have acute myeloid leukemia or myelodysplastic syndrome.
NCT00004871 ↗ Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed Sidney Kimmel Comprehensive Cancer Center Phase 1 2000-05-01 RATIONALE: Azacitidine plus phenylbutyrate may help leukemia cells develop into normal white blood cells. PURPOSE: Phase I trial to study the effectiveness of combining azacitidine and phenylbutyrate in treating patients who have acute myeloid leukemia or myelodysplastic syndrome.
NCT00004871 ↗ Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Phase 1 2000-05-01 RATIONALE: Azacitidine plus phenylbutyrate may help leukemia cells develop into normal white blood cells. PURPOSE: Phase I trial to study the effectiveness of combining azacitidine and phenylbutyrate in treating patients who have acute myeloid leukemia or myelodysplastic syndrome.
NCT00005598 ↗ Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome Completed National Cancer Institute (NCI) Phase 2 2000-10-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Amifostine may improve blood counts in patients with myelodysplastic syndrome. Combining azacitidine with amifostine may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of azacitidine plus amifostine in treating patients who have myelodysplastic syndrome.
NCT00005598 ↗ Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome Completed University of Michigan Cancer Center Phase 2 2000-10-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Amifostine may improve blood counts in patients with myelodysplastic syndrome. Combining azacitidine with amifostine may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of azacitidine plus amifostine in treating patients who have myelodysplastic syndrome.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Azacitidine

Condition Name

Condition Name for Azacitidine
Intervention Trials
Acute Myeloid Leukemia 143
Myelodysplastic Syndromes 98
Myelodysplastic Syndrome 83
Leukemia 42
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Azacitidine
Intervention Trials
Leukemia 311
Leukemia, Myeloid, Acute 285
Myelodysplastic Syndromes 273
Leukemia, Myeloid 263
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Azacitidine

Trials by Country

Trials by Country for Azacitidine
Location Trials
China 237
Japan 204
France 158
Canada 146
Germany 144
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Azacitidine
Location Trials
Texas 185
California 124
New York 123
Illinois 89
Florida 82
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Azacitidine

Clinical Trial Phase

Clinical Trial Phase for Azacitidine
Clinical Trial Phase Trials
Phase 4 3
Phase 3 63
Phase 2/Phase 3 8
[disabled in preview] 508
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Azacitidine
Clinical Trial Phase Trials
Completed 163
Recruiting 151
Not yet recruiting 92
[disabled in preview] 172
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Azacitidine

Sponsor Name

Sponsor Name for Azacitidine
Sponsor Trials
National Cancer Institute (NCI) 98
Celgene Corporation 78
M.D. Anderson Cancer Center 60
[disabled in preview] 116
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Azacitidine
Sponsor Trials
Other 521
Industry 463
NIH 100
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.